Press Release - Oslo, Norway, February 22, 2024: Photocure ASA (OSE: PHO), the
Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE:
688176) has communicated today that the international multicenter Phase III
clinical study of Cevira[®] (APL-1702), the non-surgical treatment in
development for cervical high-grade squamous intraepithelial lesions (HSIL),
will be presented for the first time in the form of an oral presentation at the
2024 European Research Organization on Genital Infection and Neoplasia
(EUROGIN), held March 13-16 in Stockholm, Sweden:

· Oral presentation (Abstract No.6802) Photodynamic therapy with APL-1702 for
high-grade squamous intraepithelial lesions (HSIL): results from a randomized
phase ? global study (YHGT-CEV-R1/APRICITY)

EUROGIN, the leading international multidisciplinary Congress on Human
Papillomavirus (HPV), aims to translate scientific and evidence-based research
into clinical practice, accelerating the reduction of the burden of HPV-related
cancers and their mortality.

Read Asieris' full media release here: https://asieris.com/asieris-to-unveil
-first-ever-results-of-the-international-multicenter-phase-iii-clinical-study
-for-1702-a-non-surgical-treatment-for-cervical-hsil-at-the-2024-eurogin/

Cevira is a breakthrough photodynamic drug-device combination product that is
being developed for non-surgical treatment of high-grade precancerous lesions of
the cervix. Photocure developed Cevira through Phase 1 and Phase 2 trials, and
the global rights for development and commercialization were out-licensed to
Asieris Meditech Co., Ltd in 2019. Asieris is a global biopharma company
specializing in discovering, developing and commercializing innovative drugs for
the treatment of genitourinary tumors and other related diseases.

Note to editors:

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.
This press release may contain product details and information which are not
valid, or a product is not accessible, in your country. Please be aware that
Photocure does not take any responsibility for accessing such information which
may not comply with any legal process, regulation, registration or usage in the
country of your origin.

About Photocure ASA

Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com

For further information, please contact:

Dan Schneider
President and CEO
Photocure ASA
Email: ds@photocure.com

Erik Dahl
CFO
Photocure ASA
Tel: +4745055000
Email: ed@photocure.com

David Moskowitz
Vice President, Investor Relations
Photocure ASA
Tel: +1 202 280 0888
Email: david.moskowitz@photocure.com

Media and IR enquiries:

Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no